By Claire Paling, Senior Director, Patient Insights & Support, Precision AQ | 24 January 2024
“Partnership is not a posture but a process – a continuous process that grows stronger each year as we devote ourselves to common tasks.” John F Kennedy.
Collaboration between the pharmaceutical industry and patient organisations has always been important and should always continue to be so.
The pharmaceutical industry is widely patient focused, with around 80% of the top pharmaceutical companies citing a patient-centred approach as a core value in their organisation. It’s a broad term that takes different forms and has varying levels, but what does a truly patient-centric approach mean?
Patient centricity and patient engagement are inherently linked but are different. For Precision AQ, patient centricity is the mindset and patient engagement is the delivery; the ways in which patient centricity is delivered. With impending, industry-wide changes to measurements and reporting guidance for patient-focused drug development (PFDD) encouraging an end-to-end patient strategy, are pharmaceutical companies across the board ready for this upcoming change in 2025? To be truly patient centric throughout a product’s life cycle, industry must:
Precision AQ undertook an in-depth listening exercise to uncover how critical partnerships between the pharmaceutical industry and the third sector can be enhanced for the good of patients. There are some great partnerships out there, however, taking the time to fully understand the patient-group perspective on how these partnerships can be improved and deepened enabled Precision AQ to develop the second edition of the Good Patient Partnership Guide.
If you want to know more about these insights and recommendations, you can access the guide at https://www.precisionaq.com/the-good-patient-partnership-guide.